Stockreport

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

CervoMed Inc.  (CRVO) 
PDF -Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on [Read more]